SCHEMBL2265610

SCHEMBL2265610

Cc1cc(C=CC#N)cc(Cl)c1Nc1ccnc(NC2CCN(c3cccc(C(N)=O)c3)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.46
CYP2D6 P10635 3/20 0.46
CYP2C9 P11712 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
KCNH2 Q12809 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
JAK3 P52333 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
EPHB4 P54760 2/20 0.39
BTK Q06187 3/20 0.38
LYN P07948 2/20 0.38
TXK P42681 2/20 0.38
SYK P43405 2/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
YES1 P07947 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2265606 1.00 CYP3A4 (0.46) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL2260782 0.96 CYP3A4 (0.49) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL2260788 0.96 CYP3A4 (0.49) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL2263603 0.88 JAK2 (0.48) CYP2C9CYP2C19KCNH2JAK2JAK1
SCHEMBL2261240 0.84 JAK2 (0.51) CYP2C9CYP2C19KCNH2JAK2JAK1
SCHEMBL2266932 0.84 CYP2C9 (0.56) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL2266935 0.84 CYP2C9 (0.56) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19
SCHEMBL12367088 0.76 CNR1 (0.46) JAK2JAK1JAK3CNR1CNR2
SCHEMBL12367091 0.74 PHGDH (0.48) CNR1CNR2SYK
SCHEMBL2265996 0.73 CYP3A4 (0.55) CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089384-B1 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-05 EP claimed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US claimed
EP-2089384-A2 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-08-19 EP claimed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US claimed
WO-2008071587-A2 2-(PIPERIDIN-4-YL)-4-PHENOXY- OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A CYP3A4 832/4885CYP2D6 823/4885CYP2C9 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.